GSK to Build £400 Million Cambridge R&D Center, Shifting from Stevenage

GSK announced that it plans to build a new flagship R&D center on the Cambridge Biomedical Campus in the United Kingdom, investing £400 million (US$532 million) over 3 years to relocate its R&D operations from Stevenage, Hertfordshire, to a new 300,000-square-foot site housing more than 1000 scientists.¹

"This investment will accelerate our R&D and help us deliver new, competitive products," said Luke Miels, chief executive officer of GSK, in a company press release.¹ "It integrates GSK further into one of the world's leading centers of knowledge and demonstrates the attractiveness of the UK's life sciences ecosystem."

What will the new Cambridge site include?

The new site, being developed by Prologis, sits within the Cambridge Biomedical Campus, one of the largest biomedical campuses in Europe, according to GSK. The site is home to more than 22,000 life sciences workers and over 470 biopharma, biotech, and artificial intelligence companies, with more than 1 million patients treated on campus annually.¹ The facility will focus on GSK's oncology, respiratory, hepatology, vaccines, and HIV research programs.

What financial context surrounds the announcement?

The announcement came alongside GSK's second-quarter 2026 earnings results, in which the company reported sales of £8.4 billion (US$11 billion), up 5% at constant currency, while total operating profit fell sharply after a £1.334 billion (US$1.76 billion) impairment tied to the discontinuation of camlipixant, an investigational chronic cough treatment that did not advance past phase 3 testing.² GSK also said it now expects to initiate more than 20 phase 3 trials in 2026, up from a previous target of 10, as part of a broader push to accelerate its late-stage pipeline.²

Separately, the company outlined a 3-year cost-reduction program targeting £1.9 billion (US$2.5 billion) in annual savings by 2029, at an estimated execution cost of £2.4 billion (US$3.2 billion), with savings earmarked primarily for R&D reinvestment and to help offset margin pressure as the HIV medicine dolutegravir faces patent expiry in the United States and European Union between 2028 and 2030.²

How does this shift fit the wider Cambridge life sciences landscape?

GSK's move places its flagship UK R&D site on a campus that already hosts AstraZeneca's Cambridge discovery center, a roughly £330 million (US$439 million) facility that anchors that company's oncology and other research, according to AstraZeneca.³ The GSK site will sit alongside collaborations already active on campus, including the Cambridge Centre for Data-Driven Discovery, the Cambridge-GSK Translational Immunology Collaboration, the Cambridge-GSK Metabolic Science Collaboration, Cambridge Immune Ageing, the GSK-Teichmann Lab, and GSK's Clinical Unit at Addenbrooke's Hospital.¹

"Cambridge has built one of the world's best life sciences ecosystems, with leading universities, hospitals, and biotech companies," said Tony Wood, PhD, chief scientific officer of GSK, in the release.¹ "With our existing connections and experience, we see this move as a catalyst for faster, bolder medicines discovery by accelerating the science that matters most for GSK's next wave of medicines."

What happens to Stevenage and Ware?

GSK will vacate its Stevenage site, where it has operated for approximately 50 years, through a phased employee move to be completed by 2029 while also upgrading its Ware, Hertfordshire, laboratories to support integrated drug development and commercial manufacturing scale-up.¹ London will remain GSK's global headquarters, unaffected by the announcement. The £400 million (US$532 million) Cambridge investment sits within GSK's broader R&D spending, which the company said exceeds £6 billion (US$8 billion) annually, including more than £1.5 billion (US$2.0 billion) in the UK.¹

References

1. GSK. GSK to establish new flagship R&D center on Cambridge Biomedical Campus, UK. Press release. Published July 28, 2026. Accessed July 28, 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/
2. GSK. GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Press release. Published July 28, 2026. Accessed July 28, 2026. https://www.investegate.co.uk/announcement/rns/gsk--gsk/2nd-quarter-results/9691506
3. AstraZeneca. AstraZeneca to invest £330 million in new strategic R&D centrer and blobal headquarters in Cambridge. Press release. Published March 18, 2013. Accessed July 28, 2026. https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-research-development-centre-global-headquarters-cambridge-18032013.html